Discovery points to ketamine’s long-term antidepressant effects

Vanderbilt University | 07-28-2021
Discovery points to ketamine’s long-term antidepressant effects
Discovery points to ketamine’s long-term antidepressant effects. Credit: © Makaule – Depositphotos

Building on recent research confirming how ketamine induces rapid antidepressant action, Professor of Pharmacology Lisa Monteggia and her collaborators show how a molecular mechanism involving methyl-CpG-binding protein 2 (MeCP2) and associated synaptic adaptability are critical to the long-term antidepressant effects of ketamine.

While MeCP2 has been shown to be important for typical antidepressants, this research indicates that, in cooperation with ketamine’s initial target, the protein is important for long-term antidepressant action, Monteggia said. The researchers discovered that MeCP2 influences ketamine’s behavioral effect as well as potentiation—the strengthening of synapses—improving its antidepressant effects over time. This work also shows that the long-term effects of ketamine involve synaptic adaptability, or plasticity—not simply structural changes. Monteggia and her team went on to show that repeated exposure to ketamine further strengthened synaptic plasticity—eliciting more plasticity of plasticity—which the team termed “metaplasticity.” This may explain why repeated doses of ketamine produce a cumulative and prolonged effect.

“We think we have the pathway in the brain to engage these long-term effects,” said Monteggia, also director of the Vanderbilt Brain Institute. “To have an impact on treatment or clinical drug development, you must know the processes in the brain that are involved. This is the first research that gives us an explanation for how ketamine produces long-term effects involving synaptic plasticity in the brain and why ketamine has cumulative antidepressant effects—a huge step forward.”

This discovery will allow researchers to target the neural pathway that prolongs ketamine’s antidepressant effects without the drug itself. While ketamine has significant promise, it also carries abuse liabilities, as the drug can trigger psychomedical effects. At low doses, the drug is not harmful, but no one knows the outcome of sustained use of ketamine to date. This discovery may be a way to circumvent the unintended and still unknown negative effects of ketamine exposure.

With the knowledge that MeCP2 can regulate gene expression, researchers are now looking to understand the underlying neural pathway more fully and to find commonalities with other antidepressants to extend their effects.

The study appears in Nature Neuroscience.


Materials provided by Vanderbilt University. Content may be edited for clarity, style, and length.


Scholarly Search Results